Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

The primary objective of this clinical study is to evaluate the efficacy of high-dose furmonertinib combined with bevacizumab and pemetrexed (triple therapy) in the treatment of non-small cell lung cancer (NSCLC) with leptomeningeal metastasis and epidermal growth factor receptor mutation (EGFRm) through overall survival (OS). The secondary objectives are to further assess the efficacy of the triple therapy in patients with EGFRm and leptomeningeal metastasis, including time to treatment failure (TTF), leptomeningeal objective response rate (ORR-LM), and clinical response rate.The study will a

Trial Details

NCT ID
NCT06643000
Phase
NA
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • furmonertinib
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Have obtained written informed consent from the patient or his or her legal representative;
  • The patient is ≥18 years old, male or female;
  • Non-small cell lung cancer confirmed by histological or cytological pathology;
  • Genetic testing confirming positive for classical or non-classical EGFR mutations;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →